Efficacy and Safety of Etanercept Treatment in Patients With Juvenile Idiopathic Arthritis Without Systemic Manifestations. The Results of an Open Prospective Study on the Basis of the Scientific Center of Children's Health (Moscow)

Алексеева, Е. И.; Бзарова, Т. М.; Валиева, С. И.; Денисова, Р. В.; Исаева, К. Б.; Чистякова, Е. Г.; Чомахидзе, А.М.; Слепцова, Т. В.; Фетисоваи, А. Н.; Ломакина, О. Л.; Тайбулатов, Н. И.; Карасёва, А. В.

doi:10.15690/vsp.v15i5.1621

Cited by 1 publication

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Проведен анализ данных проспективного когортного исследования, результаты которого были опубликованы ранее [11,19].…”

Section: дизайн исследованияunclassified

“…Исследование проведено на базе ревматологического отделения ФГАУ «Научный медицинский исследовательский центр здоровья детей» Минздрава России (Москва). В исследование включали пациентов с ЮИА без системных проявлений, которым назначался этанерцепт в период с декабря 2009 г. по август 2014 г. В указанный период этанерцепт применяли у большего числа больных, однако в настоящей статье описываются результаты анализа данных ранее проведенного проспективного исследования [19].…”

Section: условия проведенияunclassified

“…Ограничения исследования связаны с особенностями выборки пациентов. В анализ включены данные 197 пациентов, получавших этанерцепт, из ранее проведенного проспективного исследования [19], в которое, помимо данных пациентов, в отдельную группу были включены 200 пациентов, получающих метотрексат без сопутствующей терапии ГИБП. В период с декабря 2009 г. по август 2014 на базе отделения, в котором проводилось настоящее исследование, этанерцепт был назначен большему числу пациентов.…”

Section: ограничения исследованияunclassified

“…Studio, версия 1.0.136 (Free Software Foundation Inc., США) с R-пакетами версии 3.3.1 (The R Foundation for Statistical Computing, Австрия). экспертиза Первичное исследование[19] было одобрено Локаль ным этическим комитетом Научного медицинского исследовательского центра здоровья детей (протокол № 36 от 16 октября 2008 г.). Представителями пациентов, а также самими пациентами в возрасте старше 14 лет было подписано информированное согласие на введение этанерцепта.…”

unclassified

See 3 more Smart Citations

Early Prognostic Factors for Remission Achievement at Etanercept Therapy in Patients with Juvenile Idiopatic Arthritis Without Systematic Manifestations: Prospective Cohort Study

Алексеева

Дворяковская

Исаева

et al. 2019

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Background. Prognosis of therapy results of patients with the juvenile idiopatic arthritis (JIA) without systematic manifestations is the precondition of their treatment efficiency enhancement.Objective. Our aim was to establish early predictors for remission achievement in patients with JIA without systematic manifestations who received Etanercept therapy.Methods. In prospective cohort study the therapy results of patients with JIA without systematic manifestations hospitalized from December, 2009 to August, 2014 and administrated with Etanercept are analysed. The association of initial demographic indicators as well as initial and registered after a month of treatment clinical and laboratory indicators with remission achievement after a year of treatment according to the Wallace criteria is estimated.Results. The research included 197 patients with JIA without systematic manifestations who received Etanercept in 0.4 mg/kg dose twice a week subcutaneously (the maximum single dose — 25 mg). In addition to Etanercept 136 (69%) patients received Methotrexat, 121 (61%) — non-steroidal anti-inflammatory drugs, 10 (5%) — glucocorticosteroids, 6 (3%) — Sulfasalazine. After a year of treatment remission was recorded in 77 out of 197 (39.1%) patients. According to multivariate analysis the remission predictors are the following: tender joint count 4 (odds ratio (OR) 4.38; 95% confidential interval (CI) 2.33–8.55), duration of illness before Etanercept therapy 2 years (OR 1.28; 95% CI 1.02–2.15), disease activity decline according to JADAS71 index 10 points in a month of the therapy including Etanercept (OR 2.59; 95% CI 1.38–5.03). Model sensitivity was 32% (all three criteria in 25/77 patients with remission), specificity — 94% (lack of even one criteria in 113/120 patients who did not achieve remission).Conclusion. The predictors of remission in patients with JIA without systematic manifestations in 1 year of Etanercept therapy are smaller tender joint count prior to therapy, smaller duration of illness as well as significant disease activity decline in a month of the therapy.

show abstract

Section: дизайн исследованияunclassified

Section: условия проведенияunclassified

Section: ограничения исследованияunclassified

unclassified

See 2 more Smart Citations

Early Prognostic Factors for Remission Achievement at Etanercept Therapy in Patients with Juvenile Idiopatic Arthritis Without Systematic Manifestations: Prospective Cohort Study

Алексеева

Дворяковская

Исаева

et al. 2019

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

show abstract

Efficacy and Safety of Etanercept Treatment in Patients With Juvenile Idiopathic Arthritis Without Systemic Manifestations. The Results of an Open Prospective Study on the Basis of the Scientific Center of Children's Health (Moscow)

Abstract: Background: Addition of genetically engineered biological agents in the paradigm of juvenile idiopathic arthritis (JIA) treatment significantly increased the efficacy of the antirheumatic therapy in patients with

Cited by 1 publication

References 15 publications

Early Prognostic Factors for Remission Achievement at Etanercept Therapy in Patients with Juvenile Idiopatic Arthritis Without Systematic Manifestations: Prospective Cohort Study

Early Prognostic Factors for Remission Achievement at Etanercept Therapy in Patients with Juvenile Idiopatic Arthritis Without Systematic Manifestations: Prospective Cohort Study

Contact Info

Product

Resources

About